Condition: Methamphetamine Use Disorder · Methamphetamine-induced Psychosis · Sponsor: Elazığ Mental Health and Diseases Hospital
This cross-sectional observational case-control study aimed to examined serum levels of leucine-rich repeat and fibronectin type III domain-containing protein 5 (LRFN5) and olfactomedin-4 (OLFM4) levels in methamphetamine use disorder (MUD), methamphetamine-induced psychotic disorder (MP), and healthy control (HC) groups. The study also aimed to assessed systemic inflammation using the Aggregate Index of Systemic Inflammation (AISI) and examined associations between biomarkers and clinical symptom severity, including Insight Assessment Scale (IAS) and Positive and Negative Syndrome Scale (PANSS) scores.
This description comes directly from the study's public registry record.
Mehmet Hamdi ÖRÜM, MD, Assoc. Prof., Psychiatrist · +905382207558 · mhorum@hotmail.com
Always discuss trial participation with your own doctor first.
| Elazığ Mental Health and Diseases Hospital | Elâzığ, Elâzığ, Turkey (Türkiye) | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07450027